NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

NCT00391027

CompletedPhase 4

Sponsor: Pfizer

Conditions: Diabetes Mellitus, Type 2

Interventions: Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®)

Countries: Belgium, Finland, France, Germany, Netherlands, Norway, Poland, Spain

To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.

Eligibility overview

Sex: ALL

Age: 30 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diabetes Mellitus, Type 2 on oral agents
* Age \> 30 years

Exclusion Criteria:

* Severe Asthma, severe Chronic Obstructive Pulmonary Disease
* Smoking

Locations (62)

Bornem, Belgium
Brussels, Belgium
Genk, Belgium
Liège, Belgium
Kuopio, Finland
Lahti, Finland
Oulu, Finland
Besançon, France
Corbeil-Essonnes, France
La Rochelle, France
Marseille, France
Paris, France
Valenciennes, France
Altenburg, Germany
Eisenach, Germany
Hamburg, Germany
Hohenmölsen, Germany
Leipzig, Germany
Neuss, Germany
Riesa, Germany
Wangen / Allgaeu, Germany
's-Hertogenbosch, Netherlands
Eindhoven, Netherlands
Nijmegen, Netherlands
The Hague, Netherlands
Venlo, Netherlands
Hønefoss, Buskerud, Norway
Bergen, Norway
Jessheim, Norway
Lysaker, Norway
+ 32 more on CT.gov